TORONTO, Dec. 19 /CNW/ - Tm Bioscience Corporation (Toronto, Ontario; TSX: TMC), a leader in the commercial genetic testing market, today announced that it has closed its previously announced offering of 5,600,000 common shares for gross proceeds of CDN $10,080,000. The underwriting syndicate, led by Canaccord Capital Corp. and including Versant Partners Inc. and Westwind Partners Inc., agreed to purchase 5,600,000 common shares from Tm Bioscience, on a bought deal basis, and sell them to the public at a price of $1.80 per common share, representing an aggregate issue amount of $10,080,000. As of the date hereof, after the closing, the Company has 47,715,224 common shares issued and outstanding. Net proceeds from the offering will be used for the advancement of Tm Bioscience’s pipeline of genetic tests for genetic disorders, drug metabolism and infectious diseases, and for general working capital purposes.